Mankind Pharma Slips Below Key Trend Averages

remains a strong domestic formulations story with meaningful exposure to prescription medicines, consumer healthcare and a broad distribution network across India. The larger pharma theme continues to benefit from chronic therapy growth, rising healthcare access and relatively defensive demand, but the current chart has turned weaker. Price is near ₹2,296 and is trading below both the 20-day average around ₹2,323 and the 50-day average near ₹2,355. The shorter average is also below the longer one, while the stock has been forming lower highs since the July peak around ₹2,600–2,650. That combination keeps the near-term trend under pressure. The ₹2,280–2,300 region is now the first support zone to watch; a clean break below it can expose the stock to a deeper retracement toward ₹2,220–2,250. On the upside, strength would first require a reclaim of the 20-day average, but the structure improves more meaningfully only above ₹2,350–2,370. The business backdrop remains healthy, yet the chart is still signalling that sellers retain control for now